Latest news
Search news stories
Enter a keyword to search news.
Excellent cartoon video explaining the DRMCRL breast cancer advance story
Watch this short video explaining the AR breast cancer story published recently in Nature Medicine (Hickey et al, Vol 27, 310-320; http://dx.doi.org/10.1038/s41591-020-01168-7).
[Read more about Excellent cartoon video explaining the DRMCRL breast cancer advance story]
Congratulations to Theresa Hickey - 2020 Executive Dean’s Research Award recipient
Associate Professor Theresa Hickey has been awarded the 2020 Executive Dean’s Research Award in the mid-career researcher (MCR) category. Her excellence was recognised in the areas of publication of outstanding research in high ranking, peer reviewed journals; significant contribution to successful grant applications; development and implementation of a multidisciplinary research project; significant contribution to the public awareness of health and medical science; successful commercialisation of a research idea and scholarly activities that have had, or are likely to have, a major impact on the health outcomes of individuals and/or populations.
[Read more about Congratulations to Theresa Hickey - 2020 Executive Dean’s Research Award recipient]
PRESS RELEASE! New discovery in breast cancer treatment by researchers at the University of Adelaide and the Garvan Institute for Medical Research
Associate Professor Theresa Hickey, Professor Wayne Tilley (University of Adelaide) and Associate Professor Elgene Lim (Garvan Institute) have found new evidence about the positive role of androgens in breast cancer treatment with immediate implications for women with estrogen receptor-driven metastatic disease. Read the Press Release and watch a video on how androgen receptor activation can suppress tumour activity.
Associate Professor Theresa Hickey publishes paper in Nature Medicine on a suppression role for AR in breast cancer
Androgen receptor (AR)-directed therapies are controversial in (ER)-α-positive breast cancer treatment. Associate Professor Hickey et al have published a paper entitled “The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer” that demonstrates AR activation, not suppression, exerts potent anti-tumor activity in multiple disease contexts, including resistance to standard-of-care ER and CDK4/6 inhibitors. Notably, AR agonists combined with standard-of-care agents enhanced therapeutic responses. These findings provide unambiguous evidence that AR has a tumor suppressor role in ER-positive breast cancer and support AR agonism as the optimal AR-directed treatment strategy, revealing a rational therapeutic opportunity.
